Ep#015: Enabling Personalized Medicine through Biomarkers of Response with Dr. Liz O'Day

Personalized Medicine Podcast

In episode 15, our host Oleksandr Yagensky sat down with Dr. Liz O’Day, the founder and CEO of Olaris, a biotech company that enables patients to pursue most effective personalized treatments. Liz unravels how small molecule metabolites along with machine learning can be utilized to evaluate patient-specific responses to therapeutics.
Together with Olaris, Liz is shaping the future of personalized medicine. Just two weeks ago, she was elected to the Board of Directors at Personalized Medicine Coalition in recognition of her contribution to the field.
Together with Liz, we discussed:
◦ The startup story of Olaris
◦ Biomarkers of Response (BORs)
◦ The future of biomarker panels and multi-omics
◦ Metabolite based biomarker profiling
◦ Analytical platforms used at Olaris
◦ How Olaris leverages machine-learning to find patient-specific metabolite patterns
◦ Application cases for Olaris technology in cancer treatment
◦ Three-part aim of Olaris
◦ Bringing the stakeholders in healthcare together
◦ Role of science in becoming a successful entrepreneur
◦ Common challenges faced by biotech start-ups
◦ The future of personalized medicine
Get in touch with Liz:
◦ LinkedIn: @Liz O'Day
◦ Twitter: @Lizzard0126
◦ Facebook: https://www.facebook.com/olarisBoR/
◦ Instagram: https://www.instagram.com/lizzard0126/
◦ Web: https://www.olarisbor.com/
Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com